Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).

Starting soon · Phase 2

Conditions studied: Liver Transplant; Complications, Ischemic Cholangiopathy

In brief

A prospective, open-label, single-arm, investigator-initiated study (SELIC) to evaluate the efficacy and safety of seladelpar in adult liver transplant recipients with Ischemic cholangiopathy (IC).

Key facts

Study ID

NCT07305363

Run by

University of California, San Diego

People needed

10

Starts

2026-05-01

Expected to finish

2027-12-01

Last updated by the study team

2026-04-09

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult, age ≥ 18 and < 80 years
• Diagnosis of ischemic cholangiopathy defined as non-anastomotic biliary strictures confirmed by imaging (ERCP, MRI, percutaneous cholangiogram)
• Cholestasis noted by elevated alkaline phosphatase (ALP) and gamma glutamyl transferase (GGT)
• Imaging and clinical findings present at least 4 weeks after but within 12 months of liver transplantation
• No recent hospitalization within 2 weeks before enrollment to ensure clinical stability

You may not qualify if…

• Decompensated liver disease, including but not limited to ascites requiring paracentesis, hepatic encephalopathy, or variceal bleeding.
• Pregnancy or breastfeeding.
• Current or recent (within 30 days) use of other investigational agents or fenofibrate.
• Current or recent (within 30 days) use of cyclosporine
• Known hypersensitivity or contraindication to seladelpar or its excipients.
• Severe concomitant illness (renal, cardiac, or other systemic condition) that, in the investigator's judgment, would interfere with study participation or interpretation of results.
• ALT > 150 IU/L.
• AST > 150 IU/L.
• Total bilirubin > 5 mg/dL at screening

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.